VITAGLUCIDE, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, mimics natural incretin hormones to improve blood sugar control in adults with type 2 diabetes. It enhances insulin secretion, reduces glucagon levels, slows gastric emptying, curbs appetite, and supports significant weight loss.
Additionally, VITAGLUCIDE may reduce the risk of major cardiovascular events such as stroke, heart attack, and cardiovascular-related death in individuals with type 2 diabetes and known heart disease.
